Rupatadine is a selective histamine H1 receptor antagonist and platelet activating factor (PAF) antagonist used to treat allergic rhinitis. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use.
- Mechanism
- Curator reviewed · 2 references
Rupatadine is a dual histamine H1 receptor and platelet activating (PAF) receptor antagonist. During allergic response mast cells undergo degranulation, releasing histamine and other substances. Histamine acts on H1 receptors to produce symptoms of nasal blockage, rhinorhea, itching, and swelling. PAF is produced from phospholipids cleaved by phospholipase A2. It acts to produce vascular leakage which contributes to rhinorhea and nasal blockage. By blocking both the H1 receptor and PAF receptor, rupatidine prevents these mediators from exerting their effects and so reduces the severity of allergic symptoms.
- Primary indication
- For the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older.Curator reviewed · 3 structured indications
- Formula / weight
- C26H26ClN3 · 415.97 g/mol (avg)
- First approval
- Canada, 2023
- Code names
- UR-12592
- Brand names
Resolves to
WUZYKBABMWJHDL-UHFFFAOYSA-NSMILESCC1=CC(CN2CCC(CC2)=C2C3=CC=C(Cl)C=C3CCC3=C2N=CC=C3)=CN=C1What you can answer from here — as of August 30, 2026
Which drugs share a target with Rupatadine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account